Brief: Aerovate Therapeutics Presents Novel Phase 2B/Phase 3 IMPAHCT Trial Design
18/10/2022 13:02
Oct 18 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS PRESENTS NOVEL PHASE 2B/PHASE 3
IMPAHCT
TRIAL DESIGN AT CHEST ANNUAL MEETING 2022
Source text for Eikon: ID:nGNX8mNfn5
Further company coverage: AVTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million